The legal action centers on accusations that Hims & Hers shared sensitive consumer health data with third-party advertising platforms, including Meta and Snap, while publicly claiming its services remained private and secure. Furthermore, the complaint asserts the company failed to disclose that it charged customers for prescriptions almost immediately after they submitted intake forms, contradicting promises that patients would first consult with medical providers to determine appropriate treatments.
The regulatory pressure intensified on July 29, 2026, when the Federal Trade Commission announced its own lawsuit against the firm. Shares of Hims fell $4.32—a 14.73% decline—following the revelation of these deceptive practices. Robbins LLP notes that shareholders who suffered financial losses during the defined class period may be eligible to participate. Those wishing to serve as a lead plaintiff must contact the firm before the November 2, 2026, deadline. Participation does not require an upfront cost, as the firm operates on a contingency fee basis.



Comments (0)
No comments yet. Be the first!